Principal Machine Learning Scientist, Drug Discovery Analytics

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$273K-$321K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$111,944 U.S. median for this role

Projected growth (BLS Employment Projections)

+13.7% - Much faster than average

165% above the BLS role benchmark for data and ml aggregate.

Matched to SOC 15-1252 - Data and ML aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Data From the posting source checked Jun 20, 2026

Seniority

Principal From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Late-stage From the posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Principal Machine Learning Scientist, Drug Discovery Analytics Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Principal Machine Learning Scientist to lead the development of advanced machine learning approaches that accelerate small-molecule drug discovery. This role sits at the intersection of data science, chemistry, and biology, transforming complex scientific datasets into predictive models that guide target discovery, compound design, and translational hypotheses. Working closely with experimental scientists, the Principal ML Scientist will develop cutting-edge modeling approaches that integrate chemical, biological, and phenotypic data. The successful candidate will play a key role in advancing a data-driven discovery strategy by designing predictive models, deploying innovative algorithms, and translating insights into actionable decisions that improve the speed and success of the discovery of medicines for patients with RAS-driven cancers. Key responsibilities include: Scientific Leadership: - Define and lead machine learning strategies that accelerate early-stage drug discovery. - Identify opportunities where AI and advanced analytics can

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.